101 completed. 101 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 101 | Completed 101 |
| Phase 2 | 15 | Completed 15 |
Follow Colitis: new trials by email Literature Review of Colitis trials Research Report on Colitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants ALTB-268, Placebo - Ulcerative Colitis (UC) | Phase 1 | Completed | AltruBio Inc. | 24 | 2025-11-17 | 2026-10-29 |
| A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis AC-101 - Ulcerative Colitis | Phase 1 / Phase 2 | Completed | Accro Bioscience (Suzhou) Limited | 25 | 2025-01-20 | 2026-10-28 |
| Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients. PALI-2108, PALI-2108 Placebo - Ulcerative Colitis (UC), Healthy Volunteer | Phase 1 | Completed | Palisade Bio | 89 | 2024-11-05 | 2025-08-07 |
| A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis MB310, Placebo, Vancomycin - Ulcerative Colitis | Phase 1 | Completed | Microbiotica Ltd | 29 | 2024-09-27 | 2026-06-15 |
| Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) Tulisokibart, Placebo - Colitis, Ulcerative | Phase 1 | Completed | Merck Sharp & Dohme LLC | 48 | 2024-06-13 | 2025-02-17 |
| A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants MB-001 - Ulcerative Colitis | Phase 1 | Completed | Mage Biologics | 48 | 2024-05-09 | 2025-09-30 |
| Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants OD-07656 - Inflammatory Bowel Diseases, Blau Syndrome | Phase 1 | Completed | Odyssey Therapeutics, Inc. | 101 | 2024-02-12 | 2025-02-21 |
| A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis SOR102, Placebo - Ulcerative Colitis | Phase 1 | Completed | Sorriso Pharmaceuticals, Inc. | 22 | 2023-10-24 | 2024-11-29 |
| A Study of LIV001 in Healthy Subjects and Those with Mild-to-Moderate Active Ulcerative Colitis (UC) LIV001, Placebo - Ulcerative Colitis | Phase 1 | Completed | Liveome Inc. | 38 | 2023-09-24 | 2024-12-20 |
| Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects ATH-063, Placebo - Inflammatory Bowel Diseases, Crohn Disease | Phase 1 | Completed | Athos Therapeutics Inc | 76 | 2023-04-06 | 2024-05-03 |
| High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD) Methylprednisolone - Inflammatory Bowel Diseases, Crohn Disease | Phase 1 | Completed | Stanford University | 3 | 2022-10-06 | 2024-11-26 |
| Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications XELJANZ (tofacitinib) - Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2022-08-12 | 2026-05-07 |
| A Clinical Study With Adalimumab Biosimilar Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product] - Pharmacokinetics, Safety Issues | Phase 1 | Completed | Laboratorios Richmond S.A.C.I.F. | 150 | 2022-08-01 | 2024-03-04 |
| First in Human, Single Ascending Dose Study INV-101 - Ulcerative Colitis | Phase 1 | Completed | Innovo Therapeutics, Inc. | 40 | 2022-04-21 | 2023-05-06 |
| A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis BGP-014, Placebo - Ulcerative Colitis | Phase 1 / Phase 2 | Completed | BioGaia Pharma AB | 35 | 2022-02-09 | 2025-06-26 |
| An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) BT051 200 mg, BT051 800 mg, BT051 3200 mg - Ulcerative Colitis | Phase 1 | Completed | Adiso Therapeutics | 24 | 2021-11-30 | 2024-02-08 |
| Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201 HM201, Placebo - Ulcerative Colitis, Crohn's Disease | Phase 1 | Completed | Syneos Health | 53 | 2021-11-11 | 2023-02-01 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants GSK3888130B, Placebo - Multiple Sclerosis, Colitis, Ulcerative | Phase 1 | Completed | GlaxoSmithKline | 54 | 2021-11-01 | 2025-03-26 |
| A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) MK-6194, MK-6194-matching placebo - Ulcerative Colitis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 57 | 2021-10-14 | 2025-08-29 |
| Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants Brazikumab - Healthy Participants | Phase 1 | Completed | AstraZeneca | 48 | 2021-10-11 | 2022-10-27 |
Showing 20 of 101. Sign in to see all of them.
Colitis, Ulcerative (98) · Crohn Disease (24) · Inflammatory Bowel Diseases (23) · Arthritis, Juvenile (2) · Arthritis, Psoriatic (2) · Arthritis, Rheumatoid (2) · Autoimmune Diseases (2) · Hidradenitis Suppurativa (2) · Spondylitis, Ankylosing (2) · Acquired Immunodeficiency Syndrome (1) · Blau syndrome (1) · Cholangitis, Sclerosing (1) · Cytomegalovirus Infections (1) · Dermatitis (1)
Colonic Diseases (101) · Digestive System Diseases (101) · Gastroenteritis (101) · Gastrointestinal Diseases (101) · Intestinal Diseases (101) · Inflammatory Bowel Diseases (76) · Immune System Diseases (8) · Autoimmune Diseases (4) · Skin and Connective Tissue Diseases (4) · Arthritis (3) · Bone Diseases (3) · Connective Tissue Diseases (3) · Infections (3) · Joint Diseases (3)
Fecal Microbiota Transplantation (9) · Mesalamine (6) · Adalimumab (2) · Infliximab (2) · NX-13 (2) · Vancomycin (2) · 17-ethynyl-5-androstene-3, 7, 17-triol (1) · 2'-fucosyllactose (1) · Acetylcysteine (1) · BMS-986166 (1) · CT-P13 (1) · Cannabidiol (1) · Control Groups (1) · Curcumin (1) · Cytochrome P-450 Enzyme System (1)
Stanford University (4) · Tillotts Pharma AG (3) · Amgen (2) · Bristol-Myers Squibb (2) · Genentech, Inc. (2) · Gilead Sciences (2) · GlaxoSmithKline (2) · Landos Biopharma Inc. (2) · McMaster Children's Hospital (2) · Merck Sharp & Dohme LLC (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Shire (2) · Topivert Pharma Ltd (2) · AbbVie (1) · Accro Bioscience (Suzhou) Limited (1)
United States (51) · United Kingdom (12) · Germany (11) · Canada (10) · Australia (8) · Belgium (8) · Georgia (7) · Moldova (7) · Netherlands (6) · China (5) · Poland (5) · Ukraine (5) · Hungary (4) · Israel (4) · Austria (3)
Bittoo Kanwar, MD (2) · Simon Lichtiger, MD (2) · Ali Keshavarzian, M.D. (1) · Alice H Christensen, MD, PhD (1) · Alka Goyal, MD (1) · Allan H Steinhart, MD (1) · Annegret Van der Aa, PhD (1) · Anthony Opipari, MD, PhD (1)
PMID 19408340, PMID 19714757, PMID 21317177, PMID 23059643, PMID 23542823, PMID 24557009, PMID 25162366, PMID 25185797, PMID 25647155, PMID 26595549, PMID 26802087, PMID 26822613, PMID 26893546, PMID 28349233, PMID 28778448, PMID 28827258, PMID 31784432, PMID 31792136, PMID 32161949, PMID 32306792, PMID 32325480, PMID 32763240, PMID 33676969, PMID 34606847, PMID 34880013, PMID 34969665, PMID 35014040, PMID 35262901, PMID 35365713, PMID 35428657, PMID 36732049, PMID 37004656, PMID 37302449, PMID 37952114, PMID 38365502, PMID 38580386, PMID 39707077, PMID 39787364, PMID 40236400, PMID 41242336, PMID 41895287
2016 (2), 1UL1RR025014-01 (1), 2009 (1), 2015 (1), 2018 (1), 2019 (1), 2023 (1), N01CN00035 (1), P30CA060553 (1), R03DK071851 (1)